Development of Sedative Dexmedetomidine Sublingual In Situ Gels: In Vitro and In Vivo Evaluations
Intravenous dexmedetomidine (DEX) is currently approved by the FDA for the sedation of intubated patients in intensive care units to reduce anxiety and to augment postoperative analgesia. Bradycardia and hypotension are limitations associated with the intravenous administration of DEX. In this study...
Saved in:
Main Authors: | Ayat A. Allam (Author), Nermin E. Eleraky (Author), Nadeen H. Diab (Author), Mahmoud Elsabahy (Author), Sahar A. Mohamed (Author), Hala S. Abdel-Ghaffar (Author), Nivin A. Hassan (Author), Samia A. Shouman (Author), Mervat M. Omran (Author), Sahar B. Hassan (Author), Noura G. Eissa (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2022-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Nanomedicine Fight against Antibacterial Resistance: An Overview of the Recent Pharmaceutical Innovations
by: Nermin E. Eleraky, et al.
Published: (2020) -
Dexmedetomidine: An All Sedation-in-One Drug in Critically Ill Patients with COVID-19
by: Ata Mahmoodpoor, et al.
Published: (2020) -
Sedative and Immunosuppressive Effects of Dexmedetomidine in Transplantation
by: Chen-Fang Lee, et al.
Published: (2021) -
Propofol Versus Dexmedetomidine Sedation Reduces Delirium
by: Muhammad Adnan Khan, et al.
Published: (2023) -
Dexmedetomidine hydrochloride as a long-term sedative
by: Kunisawa T
Published: (2011)